Paper: Subcutaneous Epcoritamab in Combination with R2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial

Very early data from a Phase1/2 of Subcutaneous Ecoritamab in combination with rituximab and lenolidomide (perhaps call it E=R^2?) in patients with relapsed or refractory follicular lymphoma was presented. Only 5 patients were evaluable for efficacy at the abstract data cut-off with a 100% response rate.

Read the full article here

Related Articles